// App-Quantinova.ai

: Patients’ ability to use a novel fluticasone propionate/formoterol breath-triggered inhaler (BTI) vs. budesonide/formoterol dry powder inhaler (DPI)

Researchers

Presenter

  • David Bell

Principal Investigators

  • Wolfgang Timmer

  • Lucielle Mansfield

  • Mark Lomax

  • Birgit Grothe

  • Tim Overend

Medical Centers

  • BioKinetic Europe Limited, Belfast, United Kingdom

  • Inamed GmbH, Gauting, Germany

  • Mundipharma Research Limited, Cambridge, United Kingdom

Locations

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Asthma

  • Chronic obstructive pulmonary disease

Biomarkers

  • Alpha-1-microglobulin/bikunin precursor

Drug/Treatment

  • budesonide + formoterol fuma

  • Fluticasone propionate

  • Fluticasone furoate

  • DuoResp Spiromax

  • Fluticasone

  • Budesonide

  • Formoterol

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multicenteric

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Mundipharma Deutschland GmbH & Co. KG

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved